Abstract 432P
Background
Basal cell carcinoma (BCC) is the most common cancer. Surgical excision is the primary treatment of BCC. Radiotherapy and topical therapies are other treatment options. Vismodegib inhibits the hedgehog signaling pathway that is an important mechanism of developing BCC. The study aims to evaluate the vismodegib treatment in local advanced (laBCC) and metastatic (mBCC) basal cell carcinoma.
Methods
The data of 29 patients were retrospectively reviewed. The clinical and histopathological features of the patients and adverse events of vismodegib treatment were recorded. Overall survival (OS) and progression-free survival (PFS) evaluated with Kaplan-Meier analysis.
Results
The median follow-up period was 17 months (range: 1.6-57.3). The median age at diagnosis was 73 years (range: 39-88). The percentages of female and male patients were 51.7% and 48.3%, respectively. The most common location of disease was head and neck (86.2%). The number of metastatic patients was 5 (17.2%). The most common non-skin locations of disease were lymph nodes-13.8%, bone-13.8%, lung-6.9%, and brain-6.9%. Three (10.3%) patients had Gorlin’s syndrome. Before vismodegib treatment, 15 (51.7%) patients had received radiotherapy and 18 (62.1%) patients had undergone surgery. With vismodegib treatment, the complete response rate was 27.6% and partial response 55.2%, and stable response 10.3%. Treatment responses were most frequently seen within two months from the beginning of vismodegib. The most common adverse events were fatigue-58.6%, muscle spasms-48.3%, alopecia-13.8%, and weight loss- 13.8%. A total of 8 (27.6%) patients deceased during the study period. The median OS was 43.3±9.0 months (25.6-61.1) for all patients. The median PFS in the laBCC was 15.7±1.8 months (12.2-19.3). The median PFS in the mBCC was 12.1±4.6 months (2.9-21.2). After the disease progression under vismodegib treatment, 53.8% of the patients received chemotherapy or had surgical treatment.
Conclusions
In this study, we determined that vismodegib treatment in locally advanced and metastatic BCC was well tolerated and effective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session